Roche Diagnostics Inks Second ProBNP Test Development Deal
This article was originally published in The Gray Sheet
Executive Summary
Syn X Pharma aims to bring its NT-proBNP Nexus Dx point-of-care test for the detection of congestive heart failure to the U.S. market by the second half of 2004
You may also be interested in...
Epoch Turn At Nanogen? Firm Grows ASR Menu With Stock-Swap Merger
Nanogen's $58 mil. purchase of Epoch Biosciences adds real-time PCR reagents to the firm's offerings for research institutions and clinical reference labs
Epoch Turn At Nanogen? Firm Grows ASR Menu With Stock-Swap Merger
Nanogen's $58 mil. purchase of Epoch Biosciences adds real-time PCR reagents to the firm's offerings for research institutions and clinical reference labs
Low Levels Of BNP Predict HF Risk, Framingham Heart Study Shows
A correlation between B-type natriuretic peptide (BNP) levels and heart failure risk is supported by a sub-study from the ongoing Framingham Heart Study, published in the Feb. 12 New England Journal of Medicine